Dr. Leroy Hood, Biotech Pioneer, Will Discuss the Significance of this New Approach to Health Care
ATLANTA--(BUSINESS WIRE)-- Governor Nathan Deal will proclaim September 1, 2011, as Personalized Medicine Awareness Day in Georgia and kick off a half-day program to mark the occasion at Morehouse School of Medicine.
Morehouse School of Medicine President John Maupin, DDS, MBA, will welcome Governor Deal, who will announce the proclamation and deliver an opening address. Following Gov. Deal’s remarks, Leroy Hood, MD, Ph.D., a pioneer in biotechnology and genomics, and founder of the Institute for Systems Biology in Seattle, will discuss the promise of personalized medicine for improving health care.
The program, from 1 p.m. to 4 p.m., on September 1 also will feature a panel discussion involving scientists from Morehouse School of Medicine, Emory University and Georgia Institute of Technology exploring recent advances in personalized medicine and Georgia’s leadership in this innovative health care research. Speakers include:
- David Satcher, MD, PhD, Director of the Satcher Health Leadership Institute at Morehouse School of Medicine and the 16th Surgeon General of the United States.
- Kenneth L. Brigham, MD, Associate Vice President and Director of the Predictive Health Institute at Emory University and Georgia Institute of Technology.
- Valerie Montgomery Rice, MD, Dean and Executive Vice President of Morehouse School of Medicine.
- Elizabeth Ofili, MD, MPH, Associate Dean and Director of the Clinical Research Center at Morehouse School of Medicine, national principal investigator of the WARFARIN study, a first of its kind personalized medicine study approved by the Centers for Medicare and Medicaid Services.
- Roger Simon, MD, Director of Translational Programs in Stroke and Professor of Neurology and Neurobiology at Morehouse School of Medicine.
- David Stephens, MD, Vice President of Research at Emory University’s Woodruff Health Sciences Center.
The program is being organized by Morehouse School of Medicine, Emory and Georgia Tech, all of which are part of the Atlanta Clinical and Translational Science Institute, a research consortium funded by the U.S. National Institutes of Health. Also participating are Georgia Bio and Iverson Genetic Diagnostics, Inc. of Bothell, WA. Iverson Genetic Diagnostics, Inc. has a collaboration with Morehouse School of Medicine and ACTSI in a clinical research study of a new technology that will make the practice of personalized medicine possible.
The Personalized Medicine Awareness Day program will be held at the Louis W. Sullivan National Center for Primary Care at Morehouse School of Medicine. Register here. Admission is free. The program will be followed by a reception.
Dr. Hood is a pioneer in systems approaches to biology and medicine. His research has focused on the study of molecular immunology, biotechnology and genomics. His professional career began at Caltech, where he and his colleagues developed the DNA sequencer and synthesizer and the protein synthesizer and sequencer -- four instruments that paved the way for the successful mapping of the human genome. Dr. Hood also has played a role in founding more than fourteen biotechnology companies, including Amgen, Applied Biosystems, Darwin, The Accelerator and Integrated Diagnostics.
About Atlanta Clinical and Translational Science Institute
The Atlanta Clinical & Translational Science Institute (www.ACTSI.org) at Emory University partners with Morehouse School of Medicine (MSM), Georgia Institute of Technology, and Children’s Healthcare of Atlanta (CHOA) to translate laboratory discoveries into treatments, engage communities in clinical research efforts, and train the next generation of clinical investigators. The ACTSI is a unique collaborative program that draws upon the complementary strengths of Emory, MSM, GA Tech, and CHOA in order to promote the discipline of clinical and translational science across Atlanta.
Funded by the NIH and created in 2007, the ACTSI has quickly changed the culture of collaboration and has transformed clinical and translational research across the institutions. This unique partnership, the combined talents of faculty, and synergistic research and training programs have enabled the ACTSI to implement its mission of ethical community engagement, focused education and training, and innovative support of discovery to impact all populations of the Atlanta community. The balanced collaboration of the ACTSI and substantial medical and clinical resources of the member institutions offer unparalleled expertise and resources to help mobilize academic and community partners to study and eliminate health disparities in Atlanta.
About Morehouse School of Medicine
Morehouse School of Medicine is one the nation’s most widely recognized community-based medical schools, established to recruit and train minority and other students from disadvantaged backgrounds as physicians, biomedical scientists and public health practitioners. The institution’s mission places special emphasis on primary care training; development of model community-based health services and the conduct of research and translation of discovery to benefit vulnerable populations and ultimately eliminate health inequities.
Morehouse School of Medicine annually ranks as one of the top U.S. medical schools in the percentage of graduates practicing primary care specialties. The School ranks # 1 in the first-ever study of all U.S. medical schools in the area of social mission. Such recognition underscores the vital role that Morehouse plays in the nation’s health care system. For more information about Morehouse School of Medicine, visit www.msm.edu
About Iverson Genetic Diagnostics, Inc.
Iverson Genetic Diagnostics, Inc. provides physicians with genetics-based testing to identify individual patients’ predispositions to major diseases as well as the therapeutic considerations that can improve treatment outcomes and quality of life. With its growing portfolio of genetics-based tests and assays, the company is addressing one of today’s major medical challenges by ushering in a new era of more timely, predictive, and affordable “personalized” healthcare. The Company markets the Warfarin GenoSTAT Test® to provide personalized genetic profiles of patients’ potential responses to treatment with warfarin. Iverson Genetic Diagnostics is headquartered in Bothell, Washington, part of the greater Seattle technology corridor. The company’s facilities are CLIA and CAP certified. For more information, visit www.IversonGenetics.com.
About Georgia Bio
Georgia Bio (www.gabio.org) is the private, non-profit organization promoting the life sciences industry in Georgia. Members include pharmaceutical, biotechnology and medical device companies, medical centers, universities, and other organizations involved in the research and development of products and services that improve the health and well-being of people, animals and the environment.
Charles Craig, 404-245-0591
KEYWORDS: United States North America Georgia Washington
INDUSTRY KEYWORDS: Technology Nanotechnology Health Biotechnology Clinical Trials Genetics Other Health Research Science General Health